Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel J DeAngelo

Showing results (81-90 of 320) with videos related to

Pageof 32
Sort By:
Leukemia & Lymphoma|August 11, 2011
Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panelWendy Stock, Dan Douer, Daniel J DeAngelo, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|August 19, 2023
Anaphylaxis and systemic mastocytosis controlled with KIT inhibitors in a patient with metastatic lung adenocarcinomaCamellia L Hernandez, Donna-Marie Lynch, Abby Jane Golash, et al.
British Journal of Haematology|January 8, 2011
The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocolsRachael F Grace, Suzanne E Dahlberg, Donna Neuberg, et al.
Leukemia Research|May 7, 2013
Predictive factors for all-trans retinoic acid-related differentiation syndrome in patients with acute promyelocytic leukemiaHoury Leblebjian, Daniel J DeAngelo, J Andrew Skirvin, et al.
Cell|October 16, 2012
Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AMLThanh-Trang Vo, Jeremy Ryan, Ruben Carrasco, et al.
Blood Advances|January 24, 2025
Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US expertsNicholas J Short, Ibrahim Aldoss, Daniel J DeAngelo, et al.
Leukemia Research|June 11, 2013
Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomesAlexander E Sherman, Gabriela Motyckova, K Rebecca Fega, et al.
Leukemia Research|February 14, 2014
A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemiaDaniel J Deangelo, Donna Neuberg, Philip C Amrein, et al.
Haematologica|August 10, 2023
Use, variability, and justification of eligibility criteria for phase II and III clinical trials in acute leukemiaAndrew Hantel, Marlise R Luskin, Irum Khan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 29, 2010
NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignanciesEdwin P Alyea, Daniel J DeAngelo, Jeffrey Moldrem, et al.
Pageof 32

Showing results (81-90 of 320) with videos related to

Sort By:
Pageof 32
Leukemia & Lymphoma|August 11, 2011
Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panelWendy Stock, Dan Douer, Daniel J DeAngelo, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|August 19, 2023
Anaphylaxis and systemic mastocytosis controlled with KIT inhibitors in a patient with metastatic lung adenocarcinomaCamellia L Hernandez, Donna-Marie Lynch, Abby Jane Golash, et al.
British Journal of Haematology|January 8, 2011
The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocolsRachael F Grace, Suzanne E Dahlberg, Donna Neuberg, et al.
Leukemia Research|May 7, 2013
Predictive factors for all-trans retinoic acid-related differentiation syndrome in patients with acute promyelocytic leukemiaHoury Leblebjian, Daniel J DeAngelo, J Andrew Skirvin, et al.
Cell|October 16, 2012
Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AMLThanh-Trang Vo, Jeremy Ryan, Ruben Carrasco, et al.
Blood Advances|January 24, 2025
Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US expertsNicholas J Short, Ibrahim Aldoss, Daniel J DeAngelo, et al.
Leukemia Research|June 11, 2013
Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomesAlexander E Sherman, Gabriela Motyckova, K Rebecca Fega, et al.
Leukemia Research|February 14, 2014
A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemiaDaniel J Deangelo, Donna Neuberg, Philip C Amrein, et al.
Haematologica|August 10, 2023
Use, variability, and justification of eligibility criteria for phase II and III clinical trials in acute leukemiaAndrew Hantel, Marlise R Luskin, Irum Khan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 29, 2010
NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignanciesEdwin P Alyea, Daniel J DeAngelo, Jeffrey Moldrem, et al.
Pageof 32